Form 4: Eton Pharmaceuticals CEO Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Sean Brynjelsen, President & CEO and a Director of Eton Pharmaceuticals, Inc., reported multiple transactions in common stock on July 12, 2026.

Summary

  • Option exercise/conversion: acquired 27,500 Common Stock on July 12, 2026; holds 861,194 after (Direct).
  • Option exercise/conversion: acquired 200,000 Common Stock at $1.37 ($274,000) on July 14, 2026; holds 1,061,194 after (Direct).
  • Option exercise/conversion: disposed of 27,500 Restricted Stock Units on July 12, 2026 (Direct).
  • Option exercise/conversion: acquired 200,000 Employee Stock Option on July 14, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Sean Brynjelsen — Director, Officer (President & CEO)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-12Option exercise/conversionCommon Stock27,500——861,194
2026-07-14Option exercise/conversionCommon Stock200,000$1$274.0K1,061,194
2026-07-12Option exercise/conversionRestricted Stock Units27,500——0
2026-07-14Option exercise/conversionEmployee Stock Option200,000——0

Key Dates

DateDescription
2026-07-12Option exercise/conversion (27,500 shares)
2026-07-14Option exercise/conversion (200,000 shares)
2026-07-12Option exercise/conversion (27,500 shares)
2026-07-14Option exercise/conversion (200,000 shares)

Keywords

insider transaction, Form 4, ETON, Eton Pharmaceuticals, Inc., neutral, Sean Brynjelsen

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.